Oncolytics Biotech Inc ONCY

Biotech M&A is picking back up according to BiopharmaDive

[Noteable]

September 1, 2023

In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today’s most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Enbrel, might not have become so without mergers and acquisitions.

Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market.

These deals haven’t come cheap, however, with premiums on biopharma acquisitions surpassing 100% many times in recent years. Such high prices have been due, at least in part, to the fact that biotechs were able to secure large amounts of funding from private investors and the public markets, in turn forcing potential buyers to offer up more money to lock down deals.

https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

•  

[Noteable]

While M&A took a back seat during the COVID-19 pandemic and the uncertain times that followed pharma companies ultimately need to return to their dealmaking ways to remain profitable, said Jennifer O’Brien, an M&A partner at the consulting firm West Monroe. And while the biotech giant Biogen has had some missteps and hurdles, one move in particular may foretell a brighter

[Noteable]

If you can explain to investors how your science is attacking the root cause of a disease, that’s very exciting. That gets patients excited. And when the science is real, as it is proven with ONCYs platform technology pelareorep, it gets everyone excited.

[fox7mf]

The science is exciting, but it hasn't been exciting around these parts in a while. We all eagerly await an update on PanCan/FDA goings on (13 more days Coffey), and we get a heads up about another fireside. Snoozers, let's get some BD news!!!!

[fox7mf]

As M&A activity swirls around biotechs of varying descriptions, ONCY continues to miss deadlines, keep investors guessing and advance little other than new 90-day countdowns. Thx for the exciting yr Matty boy!!!

[venture009]

Fox it s/b "years". Over the multitude of years this management have never shown they were able to raise the level of enthusiasm to see any meaningful, longlasting sp appreciation. Once again we wait to see whether they can get a deal done and like the past the market, so far, is telling us they aren't very optimistic. I hope I am wrong because like many that have been here for years

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35666988

[Noteable]

Adding to the body of knowledge  https://youtu.be/zTj9RaClSo8?feature=shared

[Noteable]

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?postid=35471173

[Noteable]

Pharmaceutical Executive: October 2023, Volume 44, Issue 10  Published on:  October 13, 2023 Management will be heavily focused on acquisitions where there are compelling strategic rationales and where the same results cannot be obtained internally or through licensing and strategic partnerships and geopolitical issues will not have a dramatic effect on drug demand or

[Noteable]

Subin Baral, EY Global Life Sciences Deals Leader, recently discussed factors that help explain the budding comeback of biopharma M&A, and what the next few months may hold, with GEN Edge. Subin Baral: We have always said an M&A comeback was a matter of when and not if. The industry fundamentals have been pretty strong, and we have been a big advocate when the market was

[Noteable]

October 10, 2023 - This summer, large biotechnology deals took a vacation. The dry spell of mergers and acquisitions could be coming to an end, though, if a recent string of buyouts is any indication.  This activity may serve as fodder to some on Wall Street who’ve been forecasting an uptick in biopharma deals. For instance, analysts at the investment firm Piper Sandler wrote in an Oct.

[Noteable]

November 07, 2023 - .... the cycle of biopharma mergers and acquisitions (M&A) has returned to one of “conscious coupling” as large pharmas desperate to replenish pipelines find the promising drug candidates they’re looking for from smaller biotechs.  Subin Baral, EY Global Life Sciences Deals Leader, recently discussed factors that help explain the budding comeback of biopharma M

[Noteable]

Baral:     I think we’re seeing what we expected to see. We said divest-to-invest will continue to be a theme. We said in our prior report that it [an M&A comeback] was a matter of time, because the industry fundamentals continue to be strong. We said the therapeutic areas where the larger unmet need will continue to be in areas such as oncology, such as immunology; that has

[CaseyL]

It's frivolous. It's pushing everything down the river without clarity.

[Noteable]

For those who talk of pushing things down the river and looking for clarity, Baral addresses this criticism through his response on those seeking clarity on insightful forecasting and future developments. And the clarity of ONCYs reproducible metastatic pancreatic cancer clinical  studies are now coming to fruition. Baral:

[Noteable]

November 30, 2023 - Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market.  These deals

[fox7mf]

Hey Note, did you happen to witness what FDA approval did for Vivos Therapeutics (sleep apnea) ? Wednesday it was trading at $4.40 usd, Thursday it closed at $41 usd. Hopefully Oncy will see a 900% boost after  AA.

[Noteable]

December 13, 2023 - PwC predicts active 2024 for pharma deals as M&A value climbs. https://endpts.com/pwc-predicts-active-2024-for-pharma-deals-as-ma-value-climbs/

[Noteable]

Barrons December 08, 2023 - Biotech Deals Are Heating Up. Why 2024 Could Be Even Hotter for M&A.  Biotech deals are heating up as the year comes to an end, and analysts say the hot streak will likely continue in coming months.  Biopharma M&A had stalled in recent years as the valuations of biotechs plunged. Biotech boards were unwilling to accept offers at prices that

[Noteable]

December 14, 2023 - Mergers and acquisitions across the pharmaceuticals and life sciences sector will reach a “healthy” level next year, with deals totaling $225 billion to $275 billion, according to professional services firm PwC’s new US Deals 2024 Outlook report.  The report points to precision medicine opportunities in oncology and immunology, areas that typically see high